The authors would like to thank Kensey Pease and Justin Smith for their assistance in data collection.
Dr. Leora Horn has uncompensated consulting positions with Bayer HealthCare Pharmaceuticals, Xcovery, Bristol-Myers Squibb, and Biodesix as well as compensated consulting positions with Merck and Genentech. No financial support was provided for this work that could have influenced its outcome. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011;16(Suppl 2):32–44.
Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011;364:947–55.
Aapro M, Andre F, Blackwell K et al. . Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol 2014;25:763–773.
Bhattacharya D, Easthall C, Willoughby KA et al. . Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract 2012;18:333–342.
Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011;35:626–630.
Marin D, Bazeos A, Mahon FX et al. . Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381–2388.
Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 2008;14:530–539.
Fromme EK, Eilers KM, Mori M et al. . How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004;22:3485–3490.
Quinten C, Maringwa J, Gotay CC et al. . Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 2011;103:1851–1858.
Basch E, Jia X, Heller G et al. . Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 2009;101:1624–1632.
Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26:331–342.
Hilliard ME, Eakin MN, Borrelli B et al. . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychol 2015;34:496–504.
Sweileh WM, Zyoud SH, Abu Nab'a RJ et al. . Influence of patients' disease knowledge and beliefs about medicines on medication adherence: findings from a cross-sectional survey among patients with type 2 diabetes mellitus in Palestine. BMC Public Health 2014;14:94.
Hugon A, Roustit M, Lehmann A et al. . Influence of intention to adhere, beliefs and satisfaction about medicines on adherence in solid organ transplant recipients. Transplantation 2014;98:222–228.
Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res 2012;12:98.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–132.
Mok TS, Wu YL, Thongprasert S et al. . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.
Barthelemy P, Asmane-De la Porte I, Meyer N et al. . Adherence and patients' attitudes to oral anticancer drugs: a prospective series of 201 patients focusing on targeted therapies. Oncology 2014;88:1–8.
Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652–661.
Nilsson JL, Andersson K, Bergkvist A et al. . Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care (Engl) 2006;15:235–237.
Timmers L, Boons CC, Kropff F et al. . Adherence and patients' experiences with the use of oral anticancer agents. Acta Oncol 2014;53:259–267.